Megan Ziola
Family · Minneapolis, MNNPI 1780342139
Payments from drug & device makers
Across 53 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cycle Pharmaceuticals Inc$78
- GSK$77
- AstraZeneca$76
- CSL Behring$61
- Incyte Corporation$59
- Pfizer$54
- plus $552 from 17 others
What the payments were for
- Food & beverage$956100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cycle Pharmaceuticals Inc | 3 | $78 |
| GSK | 4 | $77 |
| AstraZeneca | 5 | $76 |
| CSL Behring | 3 | $61 |
| Incyte Corporation | 3 | $59 |
| Pfizer | 3 | $54 |
| AbbVie | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 3 | $53 |
| Pharming Healthcare, Inc. | 3 | $52 |
| Sanofi | 3 | $50 |
| Biocryst US Sales Co., LLC | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| Baxter Healthcare | 1 | $32 |
| Genentech USA, Inc. | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Novartis | 1 | $23 |
| Verona Pharma, Inc. | 1 | $19 |
| Amgen | 1 | $19 |
| LEO Pharma Inc. | 1 | $19 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $19 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
How this compares
$956 in reported general payments places this provider in the 90th percentile of 1,121 family providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $4,845 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $4,759 |
| Azelastine Hcl | 29 | $833 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $645 |
| Fluticasone Propionate | 30 | $516 |
| Montelukast Sodium | 16 | $223 |
| Levocetirizine Dihydrochloride | 21 | $159 |
| Prednisone | 13 | $30 |
Paid to pharmacies, not to this prescriber.
Other family in Minneapolis
- Julia GourdeMinneapolis$65K
- Robin DontaMinneapolis$60K
- Kristin WeberMinneapolis$35K
- Kathleen FredellMinneapolis$28K
- Diana CzelMinneapolis$24K
- Elisa RiveroMinneapolis$16K
- Marcia SimmondsMinneapolis$10K
- Rachel StenachMinneapolis$7K
- Regina SoehnleinMinneapolis$5K
- Kathryn TietzMinneapolis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.